Elsevier

Vaccine

Volume 39, Issue 5, 29 January 2021, Pages 839-845
Vaccine

Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018

https://doi.org/10.1016/j.vaccine.2020.12.046Get rights and content

Abstract

Background

Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of myopericarditis after vaccines licensed for use in the United States.

Methods

We identified U.S. reports of myopericarditis received by VAERS during 1990–2018 that met a published case definition for myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19–49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of myopericarditis after vaccination.

Results

VAERS received 620,195 reports during 1990–2018: 708 (0.1%) met the case definition or were physician-diagnosed as myopericarditis. Most (79%) myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19–49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of myopericarditis. Data mining revealed disproportionate reporting of myopericarditis only after smallpox vaccine.

Conclusions

Despite the introduction of new vaccines over the years, myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines.

Introduction

Myocarditis (inflammation of the myocardium, or heart muscle) and pericarditis (inflammation of the pericardium, or tissue overlying the heart muscle) often occur together (termed myopericarditis), and can range in severity from mild and without symptoms, to severe [1]. Myopericarditis has many causes, including viral infections [1].

Although not establishing causality, myopericarditis has been reported after vaccinations. Myopericarditis is known to occur after administration of smallpox vaccine [2]. Amsel et al., described myocarditis in a male aged 3 months after receiving both combined diphtheria, tetanus, and pertussis (DTP) vaccine, and oral polio vaccine [3]. de Meester et al. described pericarditis after vaccination with influenza vaccine [4], Peyriere et al. described pericarditis after hepatitis B vaccine [5], and Mei et al. have described recurrent pericarditis after inactivated influenza (IIV) [6]. Except for smallpox vaccine, none of these reports described vaccines licensed for use in the United States.

Myopericarditis after live virus vaccines other than smallpox vaccine has been explored to some degree [7], [8]. Reports of myopericarditis after inactivated vaccines have been scant, mostly after IIV [4], [9], including a recently published case report attributing myocarditis to adjuvanted inactivated influenza vaccine (Fluad® , Sequirus) [9]. Further, several vaccines that are not IIV – including both live attenuated and inactivated vaccines – have been licensed for use in the United States over the past several years. To better characterize myopericarditis after vaccination, we reviewed and described reports of myopericarditis received by the Vaccine Adverse Event Reporting System (VAERS).

Section snippets

Data source

VAERS is a national spontaneous reporting system for monitoring AEs after vaccination [10]. Reports of AEs following vaccines licensed for use in the United States are accepted from healthcare providers, vaccine manufacturers, vaccine recipients and other persons and entities, including the military. Reported signs and symptoms are coded using Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PTs) [11]. MedDRA PTs are not necessarily medically confirmed diagnoses, and a

Descriptive analysis

During the analytic period, VAERS received a total of 620,195 reports. Of these reports, 708 (0.1%) either met the published case definition for myopericarditis [14] or were diagnosed by a physician as myopericarditis (Table 1). Most reports described males (79%), and most reports were classified as serious (69%), with a reported time to symptom onset of 14 days or less (72%). Median reported age was 24 years (range: 0 to 90 years): among people ≤ 18 years of age, median age was 8 years (range:

Discussion

We performed a comprehensive review of post-licensure vaccine surveillance data on myopericarditis, using both a published case definition [14] and review of medical records to identify such reports. Smallpox vaccine remained the most commonly reported vaccine, while other reported vaccines were consistent with vaccine types recommended for the given age group of the patient and therefore might reflect relative frequencies of vaccine exposures per recommended schedules for vaccination [17], [18]

Note

This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC), or the US Food and Drug Administration (FDA). Mention of a product or company name does not constitute endorsement by the CDC or FDA.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References (33)

  • M. Imazio et al.

    Management of myopericarditis

    Expert Rev Cardiovasc Ther

    (2013)
  • S.G. Amsel et al.

    Myocarditis after triple immunisation

    Arch Dis Child

    (1986)
  • R. Mei et al.

    Recurrence of pericarditis after influenza vaccination: a case report and review of the literature

    BMC Pharmacol Toxicol

    (2018)
  • H.F. Tseng et al.

    Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study

    J Intern Med

    (2012)
  • Y.J. Kim et al.

    Acute Fulminant Myocarditis Following Influenza Vaccination Requiring Extracorporeal Membrane Oxygenation

    Acute Crit Care

    (2019)
  • Medical Dictionary for Regulatory Activities. Welcome to MedDRA. https://www.meddra.org/ 2020. (last accessed 14 Jan...
  • Cited by (103)

    View all citing articles on Scopus
    1

    Currently at Division of Health Economics, Policy and Management, University of Hong Kong, School of Public Health.

    View full text